




Correction to: Long-term treatment success and safety of combined phacoemulsification plus excimer laser trabeculostomy: an 8-year follow-up study

Maik Riesen^{1,2} · Jens Funk^{1,2} · Marc Töteberg-Harms^{1,2} 

Published online: 11 March 2022

© Springer-Verlag GmbH Germany, part of Springer Nature 2022

Correction to: Graefe's Archive for Clinical and Experimental Ophthalmology
<https://doi.org/10.1007/s00417-021-05510-8>

The original version of this article unfortunately contained a mistake.

Table 4 should read as below.

This is being corrected in this publication.

The original article can be found online at <https://doi.org/10.1007/s00417-021-05510-8>.

✉ Marc Töteberg-Harms
MarcToeteberg@aol.com

¹ Department of Ophthalmology, University Hospital Zurich, Frauenklinikstrasse 24, 8091 Zurich, Switzerland

² University of Zurich, Pestalozzistrasse 3, 8091 Zurich, Switzerland

Table 4 Intraocular pressure, number of topical medications to lower IOP, and best-corrected visual acuity at baseline and postoperative

	1 day			1 week			1 month											
	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value									
	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n									
IOP* [mmHg]	161	19.3 ± 4.8	158	18.9 ± 8.6	158	-0.3 ± 8.1	0.68	115	17.2 ± 6.6	115	-1.9 ± 7.3	0.0065	120	17.0 ± 6.0	120	-2.5 ± 6.6	<0.0001	
Number of meds**	161	2.3 ± 1.2	159	1.5 ± 1.4	159	-0.7 ± 1.5	<0.0001	115	1.6 ± 1.4	115	-0.7 ± 1.4	<0.0001	120	1.8 ± 1.3	120	-0.5 ± 1.3	<0.0001	
BCVA* [decimal Snellen]	158	0.51 ± 0.24	159	0.45 ± 0.25	156	-0.06 ± 0.27	0.0044	111	0.54 ± 0.24	110	0.04 ± 0.26	0.13	109	0.62 ± 0.28	107	0.12 ± 0.29	<0.0001	
3 months																		
	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value
n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n
IOP* [mmHg]	101	14.8 ± 3.1	101	14.8 ± 3.1	101	-4.0 ± 5.3	<0.0001	76	15.3 ± 3.7	76	-3.5 ± 5.3	<0.0001	71	15.1 ± 4.0	71	-3.5 ± 5.2	<0.0001	
Number of meds**	101	1.7 ± 1.3	101	1.6 ± 1.5	101	-0.6 ± 1.5	<0.0001	75	1.6 ± 1.3	75	-0.9 ± 1.3	<0.0001	70	1.6 ± 1.3	70	-0.7 ± 1.2	<0.0001	
BCVA* [decimal Snellen]	88	0.74 ± 0.26	86	0.21 ± 0.29	86	0.21 ± 0.29	<0.0001	63	0.71 ± 0.25	62	0.17 ± 0.29	<0.0001	57	0.69 ± 0.29	56	0.20 ± 0.27	<0.0001	
12 months																		
	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value
n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n
IOP* [mmHg]	98	15.4 ± 3.7	98	15.4 ± 3.7	98	-3.1 ± 5.1	<0.0001	84	15.3 ± 3.0	84	-3.3 ± 4.7	<0.0001	68	15.0 ± 3.0	68	-3.2 ± 4.9	<0.0001	
Number of meds**	98	1.5 ± 1.3	98	1.5 ± 1.3	98	-0.9 ± 1.4	<0.0001	84	1.5 ± 1.2	84	-0.7 ± 1.2	<0.0001	68	1.7 ± 1.2	68	-0.6 ± 1.2	<0.0001	
BCVA* [decimal Snellen]	87	0.73 ± 0.25	86	0.23 ± 0.28	86	0.23 ± 0.28	<0.0001	64	0.69 ± 0.27	62	0.15 ± 0.28	<0.0001	54	0.65 ± 0.28	53	0.12 ± 0.32	0.0074	
30 months																		
	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value
n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n
IOP* [mmHg]	65	14.8 ± 3.0	65	14.8 ± 3.0	65	-3.5 ± 4.9	<0.0001	62	14.9 ± 3.9	62	-2.9 ± 4.4	<0.0001	59	14.6 ± 3.9	59	-4.2 ± 5.0	<0.0001	
Number of meds**	65	1.6 ± 1.2	65	1.6 ± 1.2	65	-0.6 ± 1.4	0.0005	61	1.8 ± 1.2	61	-0.4 ± 1.3	0.022	59	1.9 ± 1.2	59	-0.4 ± 1.3	0.035	
BCVA* [decimal Snellen]	50	0.75 ± 0.23	49	0.20 ± 0.35	49	0.20 ± 0.35	0.0002	51	0.66 ± 0.25	49	0.12 ± 0.28	0.0042	50	0.68 ± 0.26	48	0.16 ± 0.31	0.0009	
48 months																		
	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value
n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n
IOP* [mmHg]	63	14.9 ± 3.5	63	14.9 ± 3.5	63	-4.4 ± 5.6	<0.0001	52	14.5 ± 3.3	52	-4.5 ± 4.9	<0.0001	45	14.6 ± 4.9	45	-5.1 ± 6.2	<0.0001	
Number of meds**	63	1.5 ± 1.2	63	1.5 ± 1.2	63	-0.6 ± 1.2	0.0006	52	1.8 ± 1.1	52	-0.3 ± 1.3	0.12	45	1.9 ± 1.2	45	-0.2 ± 1.5	0.33	
BCVA* [decimal Snellen]	60	0.73 ± 0.23	58	0.19 ± 0.28	58	0.19 ± 0.28	<0.0001	41	0.61 ± 0.27	39	0.08 ± 0.29	0.084	37	0.67 ± 0.25	35	0.13 ± 0.31	0.019	
66 months																		
	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value	Value at visit	Δ compared to baseline	p value
n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n	Mean ± standard deviation	n
IOP* [mmHg]	47	14.0 ± 2.7	47	14.0 ± 2.7	47	-5.6 ± 4.7	<0.0001	38	14.3 ± 2.8	38	-4.6 ± 4.7	<0.0001	37	14.7 ± 3.7	37	-4.6 ± 4.5	<0.0001	
Number of meds**	47	1.9 ± 1.2	47	1.9 ± 1.2	47	-0.2 ± 1.5	0.29	39	1.8 ± 1.1	39	-0.5 ± 1.4	0.032	37	1.8 ± 1.2	37	-0.4 ± 1.4	0.056	
BCVA* [decimal Snellen]	42	0.61 ± 0.27	40	0.06 ± 0.26	40	0.06 ± 0.26	0.14	35	0.59 ± 0.28	33	0.04 ± 0.26	0.38	33	0.56 ± 0.25	31	0.06 ± 0.28	0.26	

Table 4 (continued)

	84 months				90 months				96 months						
	Value at visit		Δ compared to baseline		Value at visit		Δ compared to baseline		Value at visit		Δ compared to baseline				
	n	Mean ± standard deviation	n	Mean ± standard deviation	p value	n	Mean ± standard deviation	n	Mean ± standard deviation	p value	n	Mean ± standard deviation	n	Mean ± standard deviation	p value
IOP* [mmHg]	32	14.8 ± 2.8	32	-4.4 ± 4.8	<0.0001	24	14.7 ± 2.6	24	-4.6 ± 4.9	0.0001	27	15.4 ± 3.2	27	-3.4 ± 5.6	0.0040
Number of meds**	32	1.9 ± 1.2	32	-0.3 ± 1.4	0.15	24	1.8 ± 1.3	24	-0.4 ± 1.5	0.19	27	2.1 ± 1.2	27	-0.1 ± 1.2	0.52
BCVA* [decimal Snellen]	29	0.51 ± 0.29	28	0.01 ± 0.29	0.91	20	0.48 ± 0.27	19	0.00 ± 0.23	0.93	25	0.52 ± 0.31	24	0.05 ± 0.31	0.45

IOP, intraocular pressure; *meds*, topical medications to lower IOP; BCVA, best-corrected visual acuity

*Paired t test, **Wilcoxon signed-rank test

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.